S&P 500   3,781.99 (+2.82%)
DOW   30,242.98 (+2.55%)
QQQ   281.00 (+2.73%)
AAPL   145.38 (+2.06%)
MSFT   247.96 (+3.00%)
META   140.55 (+1.40%)
GOOGL   101.36 (+2.76%)
AMZN   121.08 (+4.49%)
TSLA   248.50 (+2.52%)
NVDA   130.71 (+4.47%)
NIO   16.67 (+7.62%)
BABA   84.15 (+4.60%)
AMD   67.91 (+2.72%)
T   15.99 (+0.57%)
MU   54.20 (+4.80%)
CGC   3.14 (+7.90%)
F   12.27 (+6.97%)
GE   67.46 (+6.07%)
DIS   100.84 (+3.82%)
AMC   8.00 (+16.28%)
PYPL   92.57 (+6.18%)
PFE   44.28 (+0.32%)
NFLX   238.27 (-0.32%)
S&P 500   3,781.99 (+2.82%)
DOW   30,242.98 (+2.55%)
QQQ   281.00 (+2.73%)
AAPL   145.38 (+2.06%)
MSFT   247.96 (+3.00%)
META   140.55 (+1.40%)
GOOGL   101.36 (+2.76%)
AMZN   121.08 (+4.49%)
TSLA   248.50 (+2.52%)
NVDA   130.71 (+4.47%)
NIO   16.67 (+7.62%)
BABA   84.15 (+4.60%)
AMD   67.91 (+2.72%)
T   15.99 (+0.57%)
MU   54.20 (+4.80%)
CGC   3.14 (+7.90%)
F   12.27 (+6.97%)
GE   67.46 (+6.07%)
DIS   100.84 (+3.82%)
AMC   8.00 (+16.28%)
PYPL   92.57 (+6.18%)
PFE   44.28 (+0.32%)
NFLX   238.27 (-0.32%)
S&P 500   3,781.99 (+2.82%)
DOW   30,242.98 (+2.55%)
QQQ   281.00 (+2.73%)
AAPL   145.38 (+2.06%)
MSFT   247.96 (+3.00%)
META   140.55 (+1.40%)
GOOGL   101.36 (+2.76%)
AMZN   121.08 (+4.49%)
TSLA   248.50 (+2.52%)
NVDA   130.71 (+4.47%)
NIO   16.67 (+7.62%)
BABA   84.15 (+4.60%)
AMD   67.91 (+2.72%)
T   15.99 (+0.57%)
MU   54.20 (+4.80%)
CGC   3.14 (+7.90%)
F   12.27 (+6.97%)
GE   67.46 (+6.07%)
DIS   100.84 (+3.82%)
AMC   8.00 (+16.28%)
PYPL   92.57 (+6.18%)
PFE   44.28 (+0.32%)
NFLX   238.27 (-0.32%)
S&P 500   3,781.99 (+2.82%)
DOW   30,242.98 (+2.55%)
QQQ   281.00 (+2.73%)
AAPL   145.38 (+2.06%)
MSFT   247.96 (+3.00%)
META   140.55 (+1.40%)
GOOGL   101.36 (+2.76%)
AMZN   121.08 (+4.49%)
TSLA   248.50 (+2.52%)
NVDA   130.71 (+4.47%)
NIO   16.67 (+7.62%)
BABA   84.15 (+4.60%)
AMD   67.91 (+2.72%)
T   15.99 (+0.57%)
MU   54.20 (+4.80%)
CGC   3.14 (+7.90%)
F   12.27 (+6.97%)
GE   67.46 (+6.07%)
DIS   100.84 (+3.82%)
AMC   8.00 (+16.28%)
PYPL   92.57 (+6.18%)
PFE   44.28 (+0.32%)
NFLX   238.27 (-0.32%)
NASDAQ:ICLR

ICON Public - ICLR Stock Forecast, Price & News

$195.67
+6.48 (+3.43%)
(As of 10/4/2022 02:30 PM ET)
Add
Compare
Today's Range
$192.05
▼
$196.93
50-Day Range
$183.25
▼
$247.50
52-Week Range
$179.95
▼
$313.00
Volume
11,333 shs
Average Volume
557,993 shs
Market Capitalization
$15.93 billion
P/E Ratio
77.65
Dividend Yield
N/A
Price Target
$271.89

ICON Public MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
39.1% Upside
$271.89 Price Target
Short Interest
Healthy
1.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of ICON Public in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
18.94%
From $10.61 to $12.62 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.15 out of 5 stars

Medical Sector

9th out of 1,087 stocks

Commercial Physical Research Industry

1st out of 16 stocks

See Top Rated MarketRank™ Stocks Here
ICLR stock logo

About ICON Public (NASDAQ:ICLR) Stock

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Stock News Headlines

September 26, 2022 | fool.com.au
ICON Public Limited Company (NASDAQ: ICLR) Share Price and News
September 26, 2022 | finance.yahoo.com
ICON plc Schedules Third Quarter 2022 Earnings Conference Call
September 22, 2022 | nasdaq.com
Interesting ICLR Put And Call Options For November 18th
September 21, 2022 | finance.yahoo.com
Are ICON Public Limited Company's (NASDAQ:ICLR) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
September 14, 2022 | msn.com
What 6 Analyst Ratings Have To Say About Icon
September 13, 2022 | finance.yahoo.com
Icon PLC (ICLR) Surges 3%: Is This an Indication of Further Gains?
September 6, 2022 | finance.yahoo.com
ICON Releases its 2021 ESG Report
September 2, 2022 | nasdaq.com
Despite lower earnings than five years ago, ICON (NASDAQ:ICLR) investors are up 79% since then
August 31, 2022 | finance.yahoo.com
ICON plc to Present at the 2022 Wells Fargo Healthcare Conference
August 25, 2022 | fool.com
ICON (NASDAQ: ICLR)
August 11, 2022 | seekingalpha.com
Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth
July 29, 2022 | finanznachrichten.de
ICON plc: ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
July 28, 2022 | seekingalpha.com
ICON Public Limited Company's (ICLR) CEO Steve Cutler on Q2 2022 Results - Earnings Call Transcript
July 28, 2022 | nasdaq.com
ICON Public Limited Company's (NASDAQ:ICLR) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
July 27, 2022 | finance.yahoo.com
Icon PLC (ICLR) Tops Q2 Earnings and Revenue Estimates
July 20, 2022 | finance.yahoo.com
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
July 14, 2022 | seekingalpha.com
Deutsche Bank lowers estimates for publicly listed CROs, cuts PT on Charles River, ICON
June 22, 2022 | msn.com
Florida leaders to discuss future of ICON Park after teen's deadly fall
June 22, 2022 | finance.yahoo.com
ICON Public Limited Company (NASDAQ:ICLR) Shares Could Be 46% Below Their Intrinsic Value Estimate
June 21, 2022 | finance.yahoo.com
ICON plc Schedules Second Quarter 2022 Earnings Conference Call
June 14, 2022 | finance.yahoo.com
Baron Funds: “We Continue to Have Conviction in ICON”
June 8, 2022 | nasdaq.com
December 2023 Options Now Available For Icon
May 23, 2022 | finance.yahoo.com
ICON plc to present at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference
May 23, 2022 | finance.yahoo.com
ICON Named Business & Finance Company of the Year and One of Forbes’ Best Employers for Diversity
May 10, 2022 | finance.yahoo.com
The five-year decline in earnings might be taking its toll on ICON (NASDAQ:ICLR) shareholders as stock falls 8.5% over the past week
See More Headlines
Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Company Calendar

Last Earnings
7/27/2022
Today
10/04/2022
Next Earnings (Confirmed)
11/02/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ICLR
CUSIP
N/A
CIK
1060955
Web
www.iconplc.com
Phone
(531) 291-2000
Fax
353-1247-6260
Employees
38,330
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$271.89
High Stock Price Forecast
$295.00
Low Stock Price Forecast
$240.00
Forecasted Upside/Downside
+39.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$2.52
Trailing P/E Ratio
77.65
Forward P/E Ratio
18.44
P/E Growth
1.14
Net Income
$153.18 million
Net Margins
2.77%
Pretax Margin
3.31%
Return on Equity
10.54%
Return on Assets
4.91%

Debt

Debt-to-Equity Ratio
0.61
Current Ratio
1.18
Quick Ratio
1.18

Sales & Book Value

Annual Sales
$5.48 billion
Price / Sales
2.91
Cash Flow
$12.21 per share
Price / Cash Flow
16.03
Book Value
$99.11 per share
Price / Book
1.97

Miscellaneous

Outstanding Shares
81,390,000
Free Float
45,578,000
Market Cap
$15.93 billion
Optionable
Optionable
Beta
1.01

Social Links


Key Executives

  • Dr. Steven A. Cutler MBA (Age 62)
    Ph.D., CEO & Director
    Comp: $3.64M
  • Mr. Brendan Brennan (Age 43)
    Chief Financial Officer
    Comp: $1.63M
  • Jonathan Curtain
    Sr. VP of Corp. & Commercial Fin.
  • Mr. Thomas N. O'Leary
    Chief Information Officer
  • Mr. Diarmaid Cunningham (Age 47)
    Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec.
  • Mr. Simon Holmes (Age 55)
    Exec. VP of Investor Relations & Corp. Devel.
  • Ms. Niamh Murphy
    Director of Corp. Communications
  • Mr. David Green
    VP of Marketing
  • Mr. Joe Cronin
    Chief HR Officer
  • Ms. Dana Lynn Poff Snr.
    Exec. VP of Program Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ICLR Stock - Frequently Asked Questions

Should I buy or sell ICON Public stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICLR shares.
View ICLR analyst ratings or view top-rated stocks.

What is ICON Public's stock price forecast for 2022?

10 brokers have issued 1-year price targets for ICON Public's shares. Their ICLR share price forecasts range from $240.00 to $295.00. On average, they anticipate the company's share price to reach $271.89 in the next twelve months. This suggests a possible upside of 39.6% from the stock's current price.
View analysts price targets for ICLR or view top-rated stocks among Wall Street analysts.

How have ICLR shares performed in 2022?

ICON Public's stock was trading at $309.70 at the beginning of the year. Since then, ICLR stock has decreased by 37.1% and is now trading at $194.83.
View the best growth stocks for 2022 here.

When is ICON Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ICLR earnings forecast.

How can I listen to ICON Public's earnings call?

ICON Public will be holding an earnings conference call on Thursday, November 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) announced its quarterly earnings data on Wednesday, July, 27th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.52 by $0.18. The medical research company earned $1.94 billion during the quarter, compared to analysts' expectations of $1.93 billion. ICON Public had a net margin of 2.77% and a trailing twelve-month return on equity of 10.54%. The company's revenue for the quarter was up 122.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.12 earnings per share.

What guidance has ICON Public issued on next quarter's earnings?

ICON Public issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $11.65-$11.85 for the period, compared to the consensus earnings per share estimate of $11.58. The company issued revenue guidance of $7.69 billion-$7.81 billion, compared to the consensus revenue estimate of $7.85 billion.

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).

What is ICON Public's stock symbol?

ICON Public trades on the NASDAQ under the ticker symbol "ICLR."

How do I buy shares of ICON Public?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ICON Public's stock price today?

One share of ICLR stock can currently be purchased for approximately $194.83.

How much money does ICON Public make?

ICON Public (NASDAQ:ICLR) has a market capitalization of $15.86 billion and generates $5.48 billion in revenue each year. The medical research company earns $153.18 million in net income (profit) each year or $2.52 on an earnings per share basis.

How many employees does ICON Public have?

The company employs 38,330 workers across the globe.

Does ICON Public have any subsidiaries?
The following companies are subsidiares of ICON Public: Addplan Inc., Aptiv Solutions, Barton & Polansky Associates Inc., Beacon Bioscience Inc., BeijingWits Medical Consulting Ltd., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Research Management, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, Cross Country Healthcare - Clinical Trial Services, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Firecrest Clinical Ltd, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc., ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság, ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Group, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, MeDiNova Research, MedPass International, MediMedia Pharma Solutions, Molecular MD Corp., MolecularMD, Oxford Outcomes Limited, Oxford Outcomes Ltd, PMG Research, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, PRA Health Sciences, Pacific Research Associates Inc., Prevalere Life Sciences Inc., PriceSpective, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., Timaq Medical Imaging, UCT (U.S.) Inc, VSK (Kenilworth) Limited, and Veeda Laboratories Ltd..
Read More
How can I contact ICON Public?

ICON Public's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The official website for the company is www.iconplc.com. The medical research company can be reached via phone at (531) 291-2000 or via fax at 353-1247-6260.

This page (NASDAQ:ICLR) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.